The development of nusinersen, a synthetic, stabilized antisense oligonucleotide (ASO) that targets the splicing of SMN2 and increases the formation of a more stable protein product, has transformed the fatal type of SMA (type 1) into a stable condition. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.